Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.
Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
J Ovarian Res. 2024 Jan 12;17(1):15. doi: 10.1186/s13048-023-01332-w.
Ovarian cancer (OVCA) is the most lethal gynecologic cancer and chemoresistance remains a major hurdle to successful therapy and survival of OVCA patients. Plasma gelsolin (pGSN) is highly expressed in chemoresistant OVCA compared with their chemosensitive counterparts, although the mechanism underlying the differential expression is not known. Also, its overexpression significantly correlates with shortened survival of OVCA patients. In this study, we investigated the methylation role of Ten eleven translocation isoform-1 (TET1) in the regulation of differential pGSN expression and chemosensitivity in OVCA cells.
Chemosensitive and resistant OVCA cell lines of different histological subtypes were used in this study to measure pGSN and TET1 mRNA abundance (qPCR) as well as protein contents (Western blotting). To investigate the role of DNA methylation specifically in pGSN regulation and pGSN-induced chemoresistance, DNMTs and TETs were pharmacologically inhibited in sensitive and resistant OVCA cells using specific inhibitors. DNA methylation was quantified using EpiTYPER MassARRAY system. Gain-and-loss-of-function assays were used to investigate the relationship between TET1 and pGSN in OVCA chemoresponsiveness.
We observed differential protein and mRNA expressions of pGSN and TET1 between sensitive and resistant OVCA cells and cisplatin reduced their expression in sensitive but not in resistant cells. We observed hypomethylation at pGSN promoter upstream region in resistant cells compared to sensitive cells. Pharmacological inhibition of DNMTs increased pGSN protein levels in sensitive OVCA cells and decreased their responsiveness to cisplatin, however we did not observe any difference in methylation level at pGSN promoter region. TETs inhibition resulted in hypermethylation at multiple CpG sites and decreased pGSN protein level in resistant OVCA cells which was also associated with enhanced response to cisplatin, findings that suggested the methylation role of TETs in the regulation of pGSN expression in OVCA cells. Further, we found that TET1 is inversely related to pGSN but positively related to chemoresponsiveness of OVCA cells.
Our findings broaden our knowledge about the epigenetic regulation of pGSN in OVCA chemoresistance and reveal a novel potential target to re-sensitize resistant OVCA cells. This may provide a future therapeutic strategy to improve the overall OVCA patient survival.
卵巢癌(OVCA)是最致命的妇科癌症,化疗耐药仍然是成功治疗和OVCA 患者生存的主要障碍。与化疗敏感的 OVCA 相比,耐药 OVCA 中血浆凝胶蛋白(pGSN)高度表达,尽管其差异表达的机制尚不清楚。此外,其过表达与 OVCA 患者的生存时间缩短显著相关。在这项研究中,我们研究了 Ten eleven 易位异构体-1(TET1)的甲基化作用在调节 OVCA 细胞中 pGSN 差异表达和化疗敏感性中的作用。
本研究使用不同组织学亚型的化疗敏感和耐药 OVCA 细胞系,通过 qPCR(定量 PCR)测量 pGSN 和 TET1 mRNA 丰度以及 Western 印迹测量蛋白含量。为了专门研究 DNA 甲基化在 pGSN 调节和 pGSN 诱导的化疗耐药中的作用,使用特定抑制剂在敏感和耐药 OVCA 细胞中抑制 DNMTs 和 TETs。使用 EpiTYPER MassARRAY 系统定量 DNA 甲基化。进行增益和失能实验以研究 TET1 和 pGSN 在 OVCA 化疗反应性中的关系。
我们观察到敏感和耐药 OVCA 细胞之间 pGSN 和 TET1 的蛋白和 mRNA 表达存在差异,顺铂降低了敏感细胞中的表达,但未降低耐药细胞中的表达。与敏感细胞相比,耐药细胞中 pGSN 启动子上游区域的低甲基化。DNMTs 的药理学抑制增加了敏感 OVCA 细胞中的 pGSN 蛋白水平,并降低了它们对顺铂的反应性,但我们未观察到 pGSN 启动子区域的甲基化水平有任何差异。TETs 的抑制导致多个 CpG 位点的过度甲基化和耐药 OVCA 细胞中 pGSN 蛋白水平降低,这也与对顺铂的反应增强有关,这些发现表明 TETs 在 OVCA 细胞中 pGSN 表达的调控中具有甲基化作用。此外,我们发现 TET1 与 pGSN 呈负相关,但与 OVCA 细胞的化疗反应呈正相关。
我们的发现拓宽了我们对 OVCA 化疗耐药中 pGSN 表观遗传调控的认识,并揭示了一种重新敏化耐药 OVCA 细胞的新潜在靶标。这可能为提高 OVCA 患者总体生存率提供未来的治疗策略。